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Aquaporins are attractive targets for ther-
apeutic intervention in the diverse condi-
tions associated with water and solute
dyshomeostasis that affect millions of
patients worldwide every year.
Aquaporin drug discovery hasmade little
progress, possibly due to a range of as-
sumptions including the intrinsic non-
druggability of the aquaporin pore,
compounded by issues with the repro-
ducibility of current assays.We challengeAquaporins facilitate the passive transport of water, solutes, or ions across biolog-
ical membranes. They are implicated in diverse pathologies including brain edema
following stroke or trauma, epilepsy, cancer cell migration and tumor angiogenesis,
metabolic disorders, and inflammation. Despite this, there is no aquaporin-targeted
drug in the clinic and aquaporins have been perceived to be intrinsically non-
druggable targets. Here we challenge this idea, as viable routes to inhibition of
aquaporin function have recently been identified, including targeting their regulation
or their roles as channels for unexpected substrates. Identifying new drug develop-
ment frameworks for conditions associated with disrupted water and solute ho-
meostasis will meet the urgent, unmet clinical need of millions of patients for
whom no pharmacological interventions are available.the persistent idea that aquaporins are
not druggable; the field is still in its infancy
and much progress is yet to be made.
Viable routes to inhibition of aquaporin
function have recently been identified, in-
cluding targeting their regulation as well
as their pores. Identifying new aqua-
porin-targeted drugs for conditions as-
sociated with disrupted water and
solute homeostasis will meet an urgent,
unmet clinical need as no pharmacologi-
cal interventions are currently available.
Inhibition of hydrogen peroxide perme-
ation through AQP1 provides a new ap-
proach to treating hypertrophic
cardiomyopathies.
Inhibition of AQP4 localization with the li-
censed drug trifluoperazine provides
compelling evidence for a new approach
to treating CNS edema.
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Water is essential for life. Consequently, its abundance within the cells and tissues of all organ-
isms is tightly controlled. Although the pathways that maintain fluid volume and internal electrolyte
concentration remain incompletely understood, aquaporin water channels play key roles [1].
Thirteen aquaporin (see Glossary) isoforms are found throughout the human body, where they fa-
cilitate a range of functions including the secretion of cerebrospinal fluid (CSF), tears, saliva, sweat,
and bile, and the concentration of urine (Table 1) [2]. Perturbation of aquaporin function can result in
diverse disorders including loss of vision, loss of skin barrier function, kidney diseases, xerostomia
(dry mouth), and the edema that follows stroke or trauma to the brain or spinal cord (Table 1) [2]. In
the case of xerostomia (which is associated with reduced aquaporin 5 (AQP5) function in the sal-
ivary gland), pharmacological activation of AQP5 has been suggested as a treatment, either by di-
rect channel agonism or by activation of a signaling pathway controlling AQP5 surface expression
[3]. In the brain, AQP4 facilitates cytotoxic edema; relocalization of AQP4 to the perivascular astro-
cyte membrane exacerbates this [4] by increasing astrocyte membrane water permeability and
possibly by regulating the endfoot membrane localization of ion channels (e.g., Kir4.1, TRPV4, or
SUR1-TRPM4) via colocalization. In a vasogenic edema model, Aqp4–/– mice developed signifi-
cantly increased intracranial pressure compared with wildtype mice, also confirming a role for
AQP4 in edema resolution [5]. Several other aquaporins are overexpressed in a variety of cancer
types (Table 1). Given the crucial role of water transport in the migration of tumor cells and of an-
giogenic endothelial cells, aquaporin inhibition has been suggested as a novel anticancer strategy
[6]. Notably, no pharmacological interventions currently exist for any pathologies of aquaporin dys-
function, which instead rely on symptom management.
Aquaporin structure, function, and classification
The identification of molecules that inhibit transport through specific aquaporin isoforms is not a
simple proposition for drug discovery on account of the high level of structural conservation within
the family [7]. The small diameter of all aquaporin pores, together with the chemical properties ofTrends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx https://doi.org/10.1016/j.tips.2021.10.009 1
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and block them is a challenging prospect [8,9].
Aquaporins are tetrameric transmembrane proteins that facilitate the passive movement of water,
small neutral solutes, and some ions across biological membranes. The driving force is an
osmotic or hydrostatic gradient for water transport, or a concentration gradient for solutes.
Each tetramer is comprised of four functional monomers in which an hour-glass-shaped pore
is formed from six transmembrane helices and two helical re-entrant loops (Figure 1A).
Aquaporins are typically categorized as either being selective for water alone (the ‘orthodox’
aquaporins, AQP0, AQP1, AQP2, AQP4, AQP5, AQP6, and AQP8) or for water and small
uncharged solutes, including glycerol and urea (the ‘aquaglyceroporins’, AQP3, AQP7, AQP9,
and AQP10). The most recently discovered family members are in a separate grouping desig-
nated as ‘superaquaporins’ (AQP11 and AQP12). However, this functional categorization does
not capture the diversity within the subgroups, with some orthodox isoforms having a broader
substrate selectivity (e.g., urea permeates AQP8; Table 1) [10]. Distinct members of all three
groups facilitate hydrogen peroxide transport; the superaquaporins facilitate both water and glyc-
erol transport when purified and reconstituted into polymersomes (although their intracellular lo-
calization makes cell-based assays challenging) [11]. The superaquaporins also share less than
35% homology with other family members [12].
Amino acid sequence alignments also support the classification of aquaporins into three groups
(Figure 2). The largest group comprises the orthodox aquaporins and non-mammalian
aquaporins with experimentally determined ion channel function [big brain (BIB), AtPIP2;1, and
Nod26]. Known mammalian aquaporin ion channels (AQP0, 1, and 6) are also included in this
group (Figure 2). AQP8 is the most distantly related member of the orthodox group, in line with
its unusual permeability properties, although other phylogenetic analyses suggest it clusters
with the superaquaporins (AQPs 11,12A, and 12B; Figure 2) [13]. The group that includes the
aquaglyceroporins (AQPs 3, 7, 9, and 10) captures the well-characterized glycerol-permeable
channels (Figure 2). Residues in loops B and D influence channel gating. Weblogo diagrams
showing relative amino acid identity (Figure 2) reveal that these domains are well conserved,
apart from loop D in the aquaglyceroporins. Deeper insight into the structure–function relation-
ships across the family will facilitate the development of new modulators for all three groups.
Controversies around current aquaporin modulators
The size and shape of aquaporin pores are understood in precise atomic detail (Figure 1A). This
has enabled a molecular-level understanding of how aquaporins allow water molecules (but not
protons) to permeate cell membranes [7] and how aquaglyceroporins facilitate the passage of
larger molecules such as glycerol [14]. Although no structural evidence exists [15], isoforms
such as human AQP6 have also been shown experimentally to mediate the flow of ions [16]. It
has been proposed that ions might be conducted either via the central pore within the
homotetramer (e.g., AQP1), through intra-subunit pores (e.g., AQP6) [17] or via cotrafficking of
aquaporins and ion channels (e.g., AQP2-TRPV4) [18] (Figure 1B). However, despite a wealth
of knowledge and intense efforts in industry and academia, no clinically useful pore-blocking
drugs for any aquaporin have yet been discovered [9]. A key issue contributing to this situation
may be the limited number of in vitro assays suitable for high-throughput screening and
validating the pharmacological regulation of aquaporin function (Figure 3). Methodological
differences in executing these assays mean that attempts to replicate prior work may also result
in equivocal outcomes. The status of many aquaporin modulators is therefore controversial, as
we discuss in the following text.2 Trends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx
Glossary
Aquaporin: these are found in all
organisms and share a common
structural architecture. The functional
aquaporin unit is a homotetramer in
which each aquaporin monomer is
composed of six transmembrane
α-helices connected by alternating
intracellular and extracellular loops. The
transmembrane domains form a
right-handed bundle around the central
pore of each monomer through which
water, solute, and in some cases, ion
transport occurs. Water transport is
facilitated by direct hydrogen bonding
between a single file of water molecules
and the family’s signature Asn-Pro-Ala
(NPA) motif and pore-lining
hydrogen-bonding sites. In the
water-selective orthodox aquaporins,
exclusion of molecules larger than water
is aided by the aromatic/arginine
constriction site. In the neutral solute
permeable aquaglyceroporins, solute
discrimination (e.g., between glycerol
and urea) depends on a complex
interplay between the solute chemistry
and the size and chemistry of the pore.
While the structural biology of the
aquaporin family is well established, the
mechanisms that regulate the
physiological function of aquaporins are
less well understood.
Edema: refers to swelling, usually as a
result of injury or inflammation,
associated with excessive fluid
accumulation. Cytotoxic cerebral edema
is the accumulation of fluid in intact cells
in the brain or spinal cord. It can be
rapidly triggered when control of
energy-dependent solute homeostasis
is disrupted, often by ATP depletion as a
result of hypoxia. Loss of control of
transmembrane solute gradients can
lead to the development of
transmembrane osmotic gradients,
which drive water influx through
aquaporins, leading to a net swelling of
brain tissue. There are no
pharmacological interventions for
cytotoxic cerebral edema, which is
life-threatening due to the physical
constraints on brain volume imposed by
the inflexible skull.
High-throughput screening:
screening using high-throughput (HTP)
assays is a drug discovery process that
involves automated equipment to allow
testing of large numbers of chemical
and/or biological compounds for a
specific biological target. HTP assays
accelerate target analysis, as large-scale
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Pharmacological blockers for orthodox aquaporins are proposed to act by occluding the intra-
subunit water-conducting pore at either the extracellular or intracellular vestibule (Figure 1B).
For example, aquaporin isoforms that contain accessible cysteine residues in the pore region
(e.g., human AQP1-Cys189) can be reversibly modified by mercury chloride (HgCl2; or other cys-
teine-reactive heavy metal compounds) to inhibit water transport [8]. Despite their undisputed im-
portance in laboratory-based assays, heavy metal compounds are not viable leads for clinical
application because of their cytotoxicity.
The data supporting the status of other aquaporin blockers are less clear. Tetraethylammonium (TEA;
Box 1) ions are proposed to block aquaporin pores reversibly by interacting with pore-lining tyrosine
residues, but the in vivo value of TEA is limited by its inhibition of other channel proteins, incomplete
block of water channel function at maximal doses, and toxicity [9]. Using Xenopus laevis oocytes
(Figure 3A), TEA reduced water fluxes of human AQP1 (Tyr186), AQP2 (Tyr178) and AQP4
(Tyr185) with IC50 values of 1.4, 6.2, and 9.4 μM, respectively [19,20]. Human AQP3 and AQP5,
which lack a tyrosine residue in this position, were not blocked by TEA [20]. However, in erythrocytes
(which also express AQP3), inhibition by Hg2+, Au2+, and Ag2+, but not TEA, was observed [21]. In
another oocyte study, TEA was found not to block AQP1 [22]. Notably, the erythrocyte study
measured cell shrinking (net water efflux; Figure 3B), rather than oocyte swelling (net water influx;
Figure 3A), as done in the experiments that first identified TEA-mediated block. While the current
gold-standard assay for studying aquaporin function is the Xenopus laevis oocyte swelling assay, a
survey of the literature suggests that it is especially susceptible to false positives, with many of the
reports of aquaporin inhibitors discovered using this assay not reproduced in mammalian expression
systems. Although no-one has yet offered a plausible explanation for this, it is crucial that this potential
shortcoming is addressed experimentally.
We propose that studies of mammalian aquaporin inhibitors should, as a minimum, use two dif-
ferent mammalian expression systems, one exogenous to allow for a clear negative control, and
one endogenous to control for overexpression artifacts prior to any in vivowork. An example from
our own work is AQP4 stably overexpressed in Madin–Darby Canine Kidney (MDCK) cells with a
non-transfectedMDCK control and primary astrocytes endogenously expressing AQP4. Asmost
mammalian aquaporins are recycled between the plasma membrane and endosomal compart-
ments (and this process is tightly regulated by a variety of intracellular signaling pathways), we
also propose that aquaporin plasma membrane abundance should also be measured (e.g., by
cell surface biotinylation [23]) to ensure that any measured changes in aquaporin function are
due to inhibition of channel function and not to changes in aquaporin membrane abundance.
Using oocytes, AqB013 (an analog of bumetamide, a loop diuretic that inhibits Na-K-Cl
cotransporters), was shown to inhibit AQP1 and AQP4 [25]. Bumetanide reduced cerebral
edema and AQP4 expression in a rodent stroke model [26]. Whether the effect was mediated
by direct blockage of AQP4, alteration of AQP4 expression, or inhibition of Na-K-Cl
cotransporters is unclear. A furosemide derivative (AqF026) increased AQP1water channel activ-
ity in oocytes and in vivo accelerated AQP1-dependent peritoneal dialysis in a rodent model. This
effect was not seen in the AQP1 null animal, suggesting AqF026 specificity [27]. The AQP1 mod-
ulatory function of both molecules has been challenged [28], although data for synthesis of
AqF026 were not provided. Overall, differences in the experimental setup make it difficult to di-
rectly compare these studies.
3,3′-(1,3-Phenylene)bis(2-propenoic acid) is marketed as AQP1 inhibitor, TC AQP1 1, on the
basis that it inhibits AQP1-mediated water flux in oocytes (IC50 8 μM) [29]. However, independentTrends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx 3
compound libraries containing
thousands of molecules can quickly be
screened in a cost-effective way. There
are no currently validated
high-throughput assays of aquaporin
function.
Symptom management:
management of symptoms without
addressing the underlying pathological
cause(s). For example, osmotherapy
using hyperosmotic saline or mannitol is
often used in an attempt to reduce
cerebral edema, despite limited
evidence of efficacy.
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permeability at 50 μM when assayed by stopped flow spectrophotometry [8]. Despite this
uncertainty, several chemical vendors currently market this compound as a validated AQP1
inhibitor.
Bacopaside II (from the traditional medicinal herbBacopamonnieri) was characterized as a selec-
tive blocker of AQP1 expressed in oocytes. The results for mice in vivo and human cardiac cells in
vitro showed that hypertrophic remodeling of the heart was caused by AQP1-mediated transport
of hydrogen peroxide, which could be prevented by treatment with bacopaside II [30]. These find-
ings suggest that inhibitors of AQP1 represent new possibilities for treating hypertrophic cardio-
myopathies [30].
The arylsulfonamide, acetazolamide, is a carbonic anhydrase inhibitor (IC50 10 nM) that is used
clinically as a diuretic and to treat glaucoma and some convulsive disorders. It blocked AQP1
[29] (IC50 5.5 μM) and AQP4 (IC50 0.9 μM) [31] in Xenopus oocytes, although some investigators
could not replicate this effect [32]. N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl) acetamide is a derivative
of acetazolamide that is active against carbonic anhydrase (IC50 72 nM), and a candidate AQP4
inhibitor [33]. Ethoxyzolamide, another carbonic anhydrase inhibitor, was reported to inhibit
human AQP4-M23-mediated water transport when tested at 20 μM [31] in oocytes. Other stud-
ies have described acetazolamide inhibition of aquaporin-mediated water transport due to the
downregulation of expression, rather than a direct inhibition of channel function [34].
N-1,3,4-Thiadiazol-2-yl-3-pyridinecarboxamide is sold as AQP4 inhibitor, TGN-020; it inhibited
water flux in oocytes expressing the M23 isoform of human AQP4 with an IC50 of 3.1 μM [35]
and reduced ischemia-induced brain edema in mice pretreated 15 min before middle cerebral
artery occlusion [36]. However, others report being unable to reproduce these results in cell-
based assays [37] or have challenged the interpretation of the data [38]. Indeed, in our hands,
TGN-020 does not inhibit AQP4 function in primary astrocytes expressing endogenous AQP4
or mammalian cell-lines overexpressing exogenous AQP4. There are also discrepancies between
experiments with TGN-020 and those using Aqp4–/– animals. TGN-020 had no effect on
stimulus-induced extracellular space (ECS) volume dynamics in the ex vivoCA1 stratum radiatum
ofAqp4+/+ rats [39], whereas in Aqp4–/–mice (with no TGN-020 treatment), the same ECS volume
changes were enhanced [40]. To our knowledge, the effect of TGN-020 has not been evaluated
in Aqp4–/– mice. Recent in vivo findings suggesting that TGN-020 administration impairs
glymphatic tracer distribution in mice [41] and slows 17O-labeled H2O distribution in rats [42]
do not clarify the mode of action of TGN-020. In the glymphatic system, the clearance of brain
waste occurs through paracellular flow. Classic tracer studies measure paracellular flow, while
the use of H2
17O captures both paracellular flow and diffusive transcellular exchange of water.
Importantly, both are AQP4-dependent, the former indirectly and the latter directly [43]. Acet-
azolamide has also been shown to inhibit glymphatic tracer distribution [44]. While its mecha-
nism of action remains to be established, it could be via inhibition of AQP4 and/or carbonic
anhydrase, which reduces CSF secretion (acetazolamide is used clinically to reduce CSF
secretion in patients with intracranial hypertension). This highlights the need for a comprehen-
sive understanding of all the potential targets of a drug before interpreting the results of in vivo
experiments.
AER-270 is sold as a selective AQP4 inhibitor (IC50 240 nM). Pharmacological inhibition of AQP4
by AER-270 was suggested to reduce central nervous system (CNS) edema and AER-271, a
pro-drug of AER-270, is the subject of a phase I trial in healthy volunteers (NCT03804476; this
trial completed enrollment in August 2019, but is yet to report any data). However, only 20%4 Trends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx
Table 1. The sites of expression, associated diseases, and established permeabilities of the 13 human aquaporins. There are no pharmacological in-
terventions to treat pathologies arising from their dysregulation
AQP
isoform






AQP0 Lens fiber cells 0.25 None Cataracts
AQP1 Red blood cells
Kidney: proximal tubule
Brain: choroid plexus























AQP4 Brain: astrocyte, ependymal cells
Kidney: collecting ducts
Lung: bronchial epithelium










5.0 Hydrogen peroxide Sjögren’s syndrome
Xerostomia
Breast cancer












Type 2 diabetes mellitus
Non-alcoholic fatty liver disease
Metabolic syndrome
AQP8 Colon and small intestine
Pancreas
Liver
No quantitative data Urea
Ammonia
Hydrogen peroxide


















No quantitative data Glycerol Obesity
AQP11 Kidney: proximal tubules
Testis
Liver
~2 Glycerol Chronic kidney disease
AQP12 Pancreas No quantitative data None Pancreatitis
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bition of rat AQP4. Despite this, AER-270 had the same effect on the water content in rat and
mouse stroke models, suggesting that the effect may be AQP4-independent [45]. AER-270 is
a known nuclear factor κB (NF-κΒ) inhibitor [usually under the name IMD-0354; N-(3,5-bisTrends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx 5
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Figure 1. Aquaporin-mediated flow of water, small neutral solutes and ions and regulation by dynamic aquaporin subcellular relocalization. (A) Overview of
aquaporin structural biology. Water molecules (red spheres) traverse the pore in single file. Two key regions facilitate water transport capacity [Asn-Pro-Ala (NPA) motifs,
green], and solute exclusion (ar/R selectivity filter, red). For some isoforms, small neutral solutes such as glycerol traverse the pore in a similar fashion. (B) Three models of
aquaporin-mediated transmembrane ion transport – direct ion transport through the aquaporin central (fifth) or monomeric (water channel) pores or cotrafficking of ion
channels to the membrane. Double-headed red arrows indicate that passive, bidirectional ion flux is possible; its direction depends upon the ion concentration gradient.
(C) Schematic representation of trafficking and recycling of aquaporins between the plasma membrane and vesicle pools. Red asterisks indicate processes that can be
modulated by aquaporin posttranslational modification (e.g., phosphorylation) and/or aquaporin–protein interactions (e.g., AQP2-actin and AQP4-calmodulin). (D)
Schematic representation of pharmacological strategies to treat conditions in which aquaporin-mediated conductance is dysregulated. Created with BioRender.com.
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Figure 2. Human aquaporin amino acid sequence homologies, generated using COBALT (Constraint-based
Multiple Alignment Tool)i. (A) Phylogenetic tree alignments were done for the complete coding sequences of proteins
AQP0 (NP_036196), AQP1 (NP_000376), AQP2 (NP_000477), AQP3 (NP_004916), AQP4 (NP_001641), AQP5
(Figure legend continued at the bottom of the next page.
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(A) (B)
(C) (D)
Figure 3. The lack of reliable in vitro assays suitable for screening and validating the pharmacological regulation of aquaporin function hinders drug
discovery. Overview of four common functional assays for aquaporin water transport. (A) The Xenopus laevis oocyte assay is regarded as the gold-standard assay in
the field, although it suffers from a lack of inter-laboratory reproducibility and is not amenable to high-throughput formats. Cell shrinkage and/or swelling can be
measured by monitoring (B) changes in calcein fluorescence in adherent mammalian cells or by stopped flow light scattering in (C) yeast protoplasts or (D)
proteoliposomes. Cell shrinkage/swelling assays have the potential to be adapted to 96- or 384-well plates, but this has yet to be robustly demonstrated on a large
screen. Created with BioRender.com.
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OPEN ACCESS(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide], and NF-κΒ inhibition can reduce CNS
water content [46], highlighting the need to consider off-target effects in in vivo studies.
The identification of clinically useful ‘aquaretics’, selective blockers of aquaporin water pores,
would present an exciting advance for the therapeutic management of edema and fluid volume
disorders. However, the inhibitory actions of TGN-020, AER-270, and other molecules discussed(NP_001642), AQP6 (NP_001643), AQP7 (NP_001161), AQP8 (NP_001160), AQP9 (NP_066190), AQP10 (NP_536354)
AQP11 (AAH40443), AQP12A (Q8IXF9), and AQP12B (AAI39749), with three non-mammalian AQPs known to have ion
channel function, Arabidopsis AtPIP2;1 (P43286), Drosophila Big Brain (NP_001260313), and soybean Nodulin-26
(NP_001236728). (B).WebLogo (version 2.8.2)ii summary diagrams illustrating amino acid sequence patterns in loop B
(two upper panels) for orthodox aquaporin channels (AQPs 1,2,4,5,6, PIP2;1 and BIB) and aquaglyceroporins (AQPs
3,7,9,10), and the sequence patterns for loop D for the same sets of AQP (two lower panels).
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Box 1. Structures of putative small molecule aquaporin inhibitors.
Several structurally unrelatedmolecules have beenproposed as aquaporin inhibitors, but inmany cases the supporting evidence is equivocal. Examples of someof themostwell-
known inhibitors are given here (see Figure I). References in bold are supportive, while those in italics challenge themolecule’s inhibitory function: [A]Migliati et al. [26]; [B] Farr et al.
[45]; [C]Huber et al. [35]; [D]Gao et al. [24]; [E] Seeliger et al. [29]; [F]Brooks et al. [19]; [G]; Nakada and Huber [33]; [H]Huber et al. [31]; [I] Pei et al. [66]; [J] Esteva-Font et al.
[28]; [K] Yang et al. [32] [N] denotes that inhibitory function has not been directly determined, but rather questioned in the reviews of the field on the basis of similarities with other
tested agents. Carbon atoms (C) are shown in grey; oxygen (O) in red; sulfur (S) in yellow; nitrogen (N) in blue, and fluorine (F)/chlorine (Cl) in green.
Trends in Pharmacological Sciences
Figure I. Structures of putative small molecule aquaporin inhibitors.
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AQP4-independent effects on brain water transport, potentially confounding the interpretation
of in vivo studies. Indeed, the proposed AQP4 inhibitor topiramate [35] has anticonvulsant andTrends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx 9
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OPEN ACCESSantiepileptic properties that are attributed to its combined effects in blocking excitatory voltage-
gated sodium channels and kainate/AMPA glutamate receptors, potentiating the inhibitory
activity of GABAA receptor signaling, and inhibiting carbonic anhydrase.
Aquaglyceroporins
A series of Au(III) compounds, including Auphen [AuIII(1,10-phenanthroline)Cl2], potently inhibit
glycerol permeation in human erythrocytes [47]. Auphen blocked NLRP3-inflammasome activa-
tion to a level comparable to knockdown of AQP3 by shRNA silencing [48]. Inhibition of AQP7 by
Auphen in an adipocyte cell model implicated specific methionine residues as likely candidate
binding sites [49]. Other Au(III) compounds have been reported to have excellent anticancer ac-
tivity, low toxicity (LD50 30 mg/kg), and low nephrotoxicity [50].
Earlier work showed that AQP3 water permeability is inhibited by 1 mM Ni2+ [47], and water and
glycerol permeability of AQP3 is inhibited by 1 mM Cu2+ [49]. Polyoxotungstates were found to
inhibit AQP3 function and impaired migration of an AQP3-expressing melanoma cell line, with
P2W18, P2W12, and P5W30 identified as the most potent [51]. Screening of a library of drug-
like small molecules using a calcein fluorescence quenching assay (Figure 3B) [52] identified
new candidate inhibitors for AQPs 3, 7, and 9 [49].
Overall, there is much promise in the rapidly expanding portfolio of new inhibitors for orthodox
aquaporins and aquaglyceroporins. However, a lack of clarity on the status of published mole-
cules, some of which are marketed as aquaporin inhibitors, needs to be addressed in order to
move the field forward, to prevent the generation of spurious in vivo data and to identify leads
that can be translated to the clinic.
Targeting aquaporin regulation in the search for new modulators
In many physiological processes, cells need to modulate their plasma membrane water and solute
permeabilities. Control via gene expression can alter water or solute permeability in the long term,
but is too slow for a rapid response. Instead, conformational changes of individual aquaporin pores
to change single-channel permeabilities (gating, observedmainly in plant andmicrobial aquaporins)
or regulation of the number of pores in the membrane (more pores resulting in higher permeability)
are strategies for a more rapid change in membrane permeability. AQP0 is gated via a protein–
protein interaction with calmodulin [53], and AQPs 6 [16] and 10 [54] are reported to be gated by
large changes in pH. While the induction of large pH changes in vivo is not feasible, the use of pep-
tide-mimetic drugs that mimic the relevant histidine residues could be explored pharmacologically.
Mammalian aquaporins are much more commonly regulated by the dynamic control of their sub-
cellular localization (Figure 1C) than they are by gating. This is best characterized for AQP2 in the
kidney-collecting duct, where activation of the Gs-coupled V2 vasopressin receptor leads to
phosphorylation of AQP2 at a C-terminal serine residue (Ser256) by protein kinase A, leading to
redistribution of AQP2-bearing vesicles to the plasmamembrane [55]. Although this has tradition-
ally been considered an idiosyncrasy of AQP2, there is a now a large body of literature describing
subcellular relocalization of most mammalian aquaporins, including AQP1, AQP3, AQP4, AQP5,
AQP7, AQP8, AQP9, and AQP10 [56]. Indeed, a static view of aquaporin localization is not con-
sistent with the need for homeostatic control in response to dynamic extracellular environments
[57] and it is increasingly clear that subcellular relocalization is a ubiquitous regulatory mechanism
across the mammalian aquaporin family.
Despite the ubiquity of aquaporin membrane insertion/removal and recycling through vesicle
pools (Figure 1C), the underlying molecular mechanisms appear to be distinct for different10 Trends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx
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example of this variation on a biological theme, in kidney cells phosphorylation of AQP4 at Ser276
enhanced lysosomal targeting of AQP4 upon internalization [57], reducing the amount of AQP4
recycled back to the membrane through the recycling endosome pathway. In contrast, phos-
phorylation of AQP4 in astrocytes led to an increase in plasma membrane abundance [4,23].
From a drug development perspective, this cell-type specificity is attractive, as it reduces the
potential for side effects. However, it also emphasizes that care must be taken to choose
appropriate in vitro models before proceeding to in vivo studies.
Direct aquaporin phosphorylation [56] (with different kinases acting on different aquaporins) has
been demonstrated for protein kinases A and C, and casein kinase II [57]. Further kinases,
including extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and Ca2+/
calmodulin-dependent protein kinase II have been implicated in aquaporin subcellular
relocalization, but clear evidence that the aquaporin is the direct target of phosphorylation is
awaited [58,59]. The initial signals that activate these kinases to phosphorylate aquaporins are
also diverse, but typically involve activation of a G protein-coupled receptor [55] or a gated ion
channel. The latter are typically from the transient receptor potential family [4], members of
which can facilitate Ca2+ influx in response to a variety of signals, including changes in membrane
tension caused by cell swelling or shrinkage [60].
As these mechanisms are subtly different for different aquaporins in different tissues, there is an
unexploited opportunity for the development of specific and selective modulators of aquaporin
function (Figure 1D). We recently demonstrated that relocalization of APQ4 in astrocytes depends
upon a direct interaction with calmodulin. Using the calmodulin-inhibiting antipsychotic drug,
trifluoperazine, AQP4 localization to the blood–spinal cord barrier was reduced after spinal cord
injury in rats, CNS edema was ablated, and functional recovery was accelerated compared
with untreated animals [4]. This study provides a blueprint for drug discovery for other
aquaporin-mediated pathologies, as was recently demonstrated in a stroke model [61].
Targeting ion channel function in the search for new modulators
The current view of AQP1-mediated conduction of ions is that ions and water are transported
through separate pathways [62], with water going through the individual pores of the subunits,
and ion transport occurring through the central pore (Figure 1B) and blocked by Cd2+, 5-hydroxy-
methyl furfural, bacopside I, and the bumetanide derivative, AqB011 [63].
AqB011 caused dose-dependent inhibition of the AQP1 ion pore, with an estimated IC50 of 14
μM, but did not interfere with water transport [64]. Molecular docking predicted the site of inter-
action to be intracellular loop D at the conserved arginine residues needed for AQP1 ion channel
gating [15]. This was confirmed bymutagenesis and electrophysiology [65]. AqB011 holds prom-
ise as a possible adjunct treatment for controlling cancer metastasis, by blocking the AQP1 ionic
conductance that facilitates cancer cell migration in AQP1-positive cancers [25,66]. The medici-
nal plant component, bacopaside I, similarly blocked the AQP1 ion channel in loop D, and
inhibited migration of AQP1-expressing colon cancer cells [63]. Based on the amino acid se-
quences of the loop D gating region, AqB011 might be expected to be selective; for example,
the plant channels AtPIP2;1 and AtPIP2;1 with different loop D domains were insensitive [67].
Ubiquitousmodulation by divalent cations is a theme seen acrossmany types of ion channels and
receptors, including N-methyl-D-aspartate (NMDA) glutamate receptors, cation channels, K+
channels, Na+ channels, and others as reviewed previously [68]. Tyrosine phosphorylation in
the C-terminal domain increased the activation of AQP1 by cGMP [69]. When key C-terminalTrends in Pharmacological Sciences, Month 2021, Vol. xx, No. xx 11
Outstanding questions
Are aquaporin pores intrinsically
undruggable or can they be blocked
with sufficient specificity by small
drug-like molecules?
Is aquaporin subcellular localization a
viable alternative target for drug
discovery?
Can we define signature motifs and
molecular mechanisms of ion
transport in relevant classes of
aquaporins?
Can a reproducible, standard assay be
established to validate aquaporin
function that has the potential to be
miniaturized for high-throughput
screening?
Trends in Pharmacological Sciences
OPEN ACCESSresidues were altered by site-directed mutagenesis, activation of the AQP1 ionic current was
impaired, but water permeability was retained [69], suggesting that intramolecular interactions
between loop D and the C-terminus might add another layer of gating control [65].
Concluding remarks and future perspectives
Aquaporins support a wide range of physiological processes; their dysregulation leads to diverse
diseases. Although they are validated drug targets, it is still unclear whether their pores are intrin-
sically undruggable or whether they can be blocked with small drug-like molecules (see
Outstanding questions). Targeting the molecular mechanisms of aquaporin subcellular
relocalization provides a compelling alternative approach for drug development, as demonstrated
for AQP4 in models of CNS edema. The definition of signature motifs and molecular mechanisms
of ion transport also provide new avenues for future drug discovery. Development of robust
assays and the validation of potential aquaporin modulators across different assay systems will
underpin the field. This will give hope to the millions of patients worldwide each year for whom
no pharmacological intervention is available.
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